Fosamax Jaw Injury Litigation News
Merck’s controversial osteoporosis medication Fosamax has been the topic of heated litigation over the past seven years. The drug has been tied to severe jaw problems, including bone and tissue necrosis, forcing many patients to endure costly surgeries and treatments. At present, the pharmaceutical giant is defending its medication in nearly 1,000 products liability complaints, which have been coordinated for pre-trial proceedings before the Honorable John F. Keegan in New York District Court. A form of consolidated litigation, the Fosamax MDL merges federal cases containing similar issues of fact and allegations concerning the drug’s adverse side effects.
In a recent order, Judge Keegan denied Merck’s request for the court to issue a “Lone Pine” order, an act that would have forced claimants who took Fosamax for less than 12 months to supply evidence and further testimony to support their claims against the defendant. This would apply to plaintiffs who were not yet diagnosed with osteonecrosis of the jaw, or if their exposure to the drug was more than three years before they sustained jaw damage.
Judge Keegan found that plaintiffs’ medical records are not always construed in the same manner, and that the court could not effectively identify those without a diagnosis of osteonecrosis of the jaw (OJN). The MDL judge also failed to see any purpose for the Lone Pine order as the court had already determined that juries would believe that Fosamax may contribute to ONJ and the standard definition of the condition is not predicated on prior exposure to the drug for a minimum period of time.
As the pre-trial process has concluded and claimants have yet to reach settlements with Merck, many are pushing to have their cases sent back to their original courts for individual hearings, in hopes of securing a jury award or settlement. With such complex litigation, it will likely take months or even years before Fosamax lawsuit plaintiffs see a dime of compensation.
LawStreet Capital is committed to providing medical device legal funding for plaintiffs with no strings attached. We know how expensive and lengthy litigation can be – it can take years to recover a settlement. With a non-recourse Fosamax lawsuit loan, you can get the money you need today to relieve economic pressures so your legal team can focus on obtaining maximum recovery.
Medical device legal funding for plaintiffs
A pre settlement cash advance from LawStreet Capital can help you hold out for the best possible settlement, freeing you from the binds of financial worries. Use the funds however you need; in addition to funding your case, you can use the cash advance to cover basic necessities such as rent, car and mortgage payments. Depending on the strength and details of your case, we can offer medical device legal funding from $500 to over $1 million at interest rates that are highly competitive.
If you’ve been injured by Fosamax and are in need of immediate cash to help tide you over, take a minute to consider our risk-free legal funding solutions. We assume all risk, as your lawsuit loan is only paid back in the event you win your case!
Apply for a Fosamax lawsuit loan today
There are tons of legal funding companies out there, so why choose Lawstreet Capital? For starters, we offer the industry’s lowest rates on pre settlement cash advances, with no obligation to proceed once your application has been approved. If you’re thinking about the advantages medical device legal funding consider the following benefits of working with us:
- Fast approval – usually within 24 hours
- No hidden costs or upfront fees
- Bad credit or no credit is unimportant
- No employment checks
- You owe us nothing if you lose your case!
- Get your Fosamax lawsuit loan overnighted or deposited into your bank the next day!
Call LawStreet Capital today for a free and confidential chat with one of our customer representatives who can begin your application process. Call anytime, toll-free at 1.866.FUND.662.
